Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2022

View Archived Issues

Hepsin contributes to metastasis and thrombosis in patients with CRC, study finds

AZD-1390 induces dramatic recovery after spinal cord injury in preclinical models

Novel CDK9 inhibitor with good antiproliferative activity in hematologic cancer models

Jiangsu Hengrui Medicine patents PTPN11 inhibitors

Korean investigators divulge new EGFR inhibitors

Praxis Precision Medicines discloses KCNT1 inhibitors

Galecto Biotech identifies new LGALS inhibitors

Tsinghua University synthesizes new NAMPT enzyme activators

PharmaCyte achieves promising interim results in study to establish malignant ascites mouse model

Viraleze antiviral nasal spray shows protection against SARS-CoV-2 Omicron in viral challenge model

Genetic variants in SLFN14 cause macrothrombocytopenia and coagulation defects

Mutation-specific targeting increases transporter protein in cystic fibrosis

PXL-770 demonstrates efficacy in models of X-Linked adrenoleukodystrophy

Cas-CLOVER, a high fidelity site-specific nuclease for the production of allogeneic CAR T cells

POU5F1 emerges as an attractive target in glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...